Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15425453 | 0.98 | ELANE (0.43) | ELANEEPHX2PTGS2ITGB2ICAM1 | |
| Formic Acid SCHEMBL15411803 | 0.98 | ELANE (0.41) | ELANEEPHX2PTGS2ITGB2ICAM1 | |
| Formic Acid SCHEMBL15411868 | 0.94 | ELANE (0.40) | ELANEEPHX2PTGS2ITGB2ICAM1 | |
| SCHEMBL15425553 | 0.92 | ELANE (0.41) | ELANEEPHX2PTGS2ITGB2ICAM1 | |
| Formic Acid SCHEMBL15411865 | 0.91 | ELANE (0.39) | ELANEEPHX2PTGS2ITGB2ICAM1 | |
| SCHEMBL15411853 | 0.91 | ELANE (0.44) | ELANEEPHX2PTGS2ITGB2ICAM1 | |
| SCHEMBL15410928 | 0.91 | ELANE (0.45) | ELANEEPHX2PTGS2ITGB2ICAM1 | |
| Formic Acid SCHEMBL15412290 | 0.91 | ELANE (0.42) | ELANEEPHX2PTGS2MALT1SLC5A1 | |
| Formic Acid SCHEMBL15411732 | 0.91 | ELANE (0.41) | ELANEMALT1ADORA2ASLC5A1MAPT | |
| SCHEMBL15411653 | 0.90 | ELANE (0.43) | ELANEEPHX2PTGS2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872509-B1 | INHIBITION OF ENZYMES | CHIESI FARMA SPA (IT) | 2016-09-14 | — | — | EP | claimed |
| US-9199984-B2 | Inhibition of enzymes | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-01 | — | — | US | claimed |
| EP-2872509-A1 | INHIBITION OF ENZYMES | Chiesi Farmaceutici S.p.A. (IT) | 2015-05-20 | — | — | EP | claimed |
| US-20140018345-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A (IT) | 2014-01-16 | — | — | US | claimed |
| WO-2014009425-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-01-16 | — | — | WO | claimed |
| EP-2872509-B1 | INHIBITION OF ENZYMES | CHIESI FARMA SPA (IT) | 2016-09-14 | — | — | EP | disclosed |
| US-9199984-B2 | Inhibition of enzymes | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-01 | — | — | US | disclosed |
| EP-2872509-A1 | INHIBITION OF ENZYMES | Chiesi Farmaceutici S.p.A. (IT) | 2015-05-20 | — | — | EP | disclosed |
| US-20140018345-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A (IT) | 2014-01-16 | — | — | US | disclosed |
| WO-2014009425-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018345-A1 | INHIBITION OF ENZYMES | SERPINB1, ELANE, MPO | ELANE 2/4885EPHX2 473/4885PTGS2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.